Joint bioequivalence testing to be permitted next year

Published: 2009-07-15 07:00:00

Updated: 2009-07-15 07:00:00

The Korea Food and Drug Administration said that the joint bioequivalence testing, which has been implemented on a limited basis, would be fully utilized by those companies which may cope with the new guideline to be formulated by a KFDA’s consultative body.

The drug agency hinted that the fut...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK